Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury.
about
Considerations and challenges in defining optimal iron utilization in hemodialysisUSPIO-Enhanced MRI Neuroimaging: A Review.MCP-1 gene activation marks acute kidney injuryRenal cortical albumin gene induction and urinary albumin excretion in response to acute kidney injury.Neutrophil gelatinase-associated lipocalin increases HLA-G(+)/FoxP3(+) T-regulatory cell population in an in vitro model of PBMC.Comparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations.Low Serum Neutrophil Gelatinase-associated Lipocalin Level as a Marker of Malnutrition in Maintenance Hemodialysis Patients.Fibroblast growth factor 23 and acute kidney injury.Recovery from glycerol-induced acute kidney injury is accelerated by suramin.Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD.Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trialThe Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationaleCombined iron sucrose and protoporphyrin treatment protects against ischemic and toxin-mediated acute renal failureRedox-sensitive glycogen synthase kinase 3β-directed control of mitochondrial permeability transition: rheostatic regulation of acute kidney injury.Testing the iron hypothesis in a mouse model of atherosclerosis.Renal cortical pyruvate depletion during AKI.Cell- and biomarker-based assays for predicting nephrotoxicity.The Labile Side of Iron Supplementation in CKDSafety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min.Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud?D-penicillamine combined with inhibitors of hydroperoxide metabolism enhances lung and breast cancer cell responses to radiation and carboplatin via H2O2-mediated oxidative stress.Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation.Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose.
P2860
Q28088564-BD78A542-3FE4-4449-A187-4C7BFC0719DFQ31051172-DB8B7BE0-F7C9-4D02-B3FA-4F0E3064B87EQ34457306-E80D2669-89CA-4C44-8BA1-5F040D33037EQ34719218-DA545718-4C8A-45A5-A39C-ADB9B0C1675EQ35107474-45561ADA-CA0B-455A-BB98-0626E3E0443AQ35631492-5094C02F-30CF-4FF2-ABC0-AE14A157E624Q35687846-C4DF21C8-38AA-403E-8395-E9FE14C43456Q35690579-3D3CC9AD-F488-4743-8F78-7D7F5DE1547DQ35847714-CF3B8C91-672B-42F3-B388-591BE437C2A2Q35857178-C54E6BD7-8BB0-4E06-8975-E6AC20DA3481Q36251928-97C760A8-CC95-44AE-9219-DD8550A21F6AQ36333126-66150D55-381D-45EB-9351-12CD9FF3E86EQ37069675-F9AD0336-EE76-43BB-9220-D72629A560A7Q37385047-0B37AB13-B606-4C03-9EE1-2DF9E78F26B8Q37430727-6D4C8D20-A970-4320-A8B1-55B296620DBBQ37733602-ACC64D2D-D255-4EF4-9F80-0DC39D454B19Q38266417-B3CAB53E-5406-4AFB-ABA4-AAAD475004CCQ38496987-63D61030-0CF8-4DD2-AFAF-25AAB87C93C3Q39390590-7444E630-08E5-4654-810D-E12855CBAF94Q42276525-6A5CE6A9-3C65-4CB5-95D1-134A17D06FDEQ46387857-35E02462-5889-4AA5-A3B2-DA02A822546EQ47805747-6F40B7FE-A0FC-4546-B2D2-BF946B3858EFQ51733222-EA60EE34-B303-4FBE-B90A-E4744DF9172E
P2860
Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Parenteral iron formulations d ...... and renal responses to injury.
@ast
Parenteral iron formulations d ...... and renal responses to injury.
@en
Parenteral iron formulations d ...... and renal responses to injury.
@nl
type
label
Parenteral iron formulations d ...... and renal responses to injury.
@ast
Parenteral iron formulations d ...... and renal responses to injury.
@en
Parenteral iron formulations d ...... and renal responses to injury.
@nl
prefLabel
Parenteral iron formulations d ...... and renal responses to injury.
@ast
Parenteral iron formulations d ...... and renal responses to injury.
@en
Parenteral iron formulations d ...... and renal responses to injury.
@nl
P2093
P2860
P1476
Parenteral iron formulations d ...... and renal responses to injury.
@en
P2093
Ali C M Johnson
Kirsten Becker
Richard A Zager
P2860
P304
P356
10.1152/AJPRENAL.00248.2010
P577
2010-05-26T00:00:00Z